US EditionManaging Dermatologic AEs With Amivantamab/Lazertinib: Updates From the COCOON Clinical Trial
Summary by cancernetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
oncnursingnews.comReposted by 
cancernetwork.com
cancernetwork.comManaging Dermatologic AEs With Amivantamab/Lazertinib: Updates From the COCOON Clinical Trial
Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and topical treatments, can reduce skin toxicities by 50% in patients receiving amivantamab plus lazertinib therapy.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium